Kataki Manjir Sarma, Kakoti Bibhuti Bhusan, Jameson Melanie, Solanki Aum, Hirani Anjali, Pathak Yashwant
College of Pharmacy, University of South Florida Health, 12901 Bruce B Downs Blvd, MDC 030, Tampa, FL 33612.
Curr Pharm Des. 2015;21(31):4587-93. doi: 10.2174/138161282131151013191051.
Drug delivery to the eye is challenging for formulation scientists due to physiological barriers that separate the eye from the rest of the body. A variety of ocular disorders demand the development of optimal drug delivery systems for the administration of drugs and therapeutic agents that can overcome barriers that restrict drug bioavailability. SiRNA inhibits the expression of target genes and has immense potential as a biological tool for the therapeutic inhibition of disease causing genes; however, delivery of siRNA to ocular tissue is a challenge. Recent literature suggests that nanoplatforms show great promise in enhancing ophthalmic drug delivery. A drug delivery system involving nanoparticles and siRNA could surpass problems faced in ocular delivery with improved biodistribution and lower toxicity. This review covers recent research in the area of nanocarrier siRNA drug delivery for various ocular disorders.
由于存在将眼睛与身体其他部位分隔开的生理屏障,药物递送至眼部对制剂科学家而言具有挑战性。多种眼部疾病需要开发优化的药物递送系统,用于给药那些能够克服限制药物生物利用度的屏障的药物和治疗剂。小干扰RNA(siRNA)可抑制靶基因的表达,作为一种用于治疗性抑制致病基因的生物学工具具有巨大潜力;然而,将siRNA递送至眼部组织是一项挑战。近期文献表明,纳米平台在增强眼科药物递送方面显示出巨大前景。一种涉及纳米颗粒和siRNA的药物递送系统可以通过改善生物分布和降低毒性来克服眼部递送中面临的问题。本综述涵盖了纳米载体siRNA药物递送用于各种眼部疾病领域的最新研究。